^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA wild-type

    i
    Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset, BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
    Entrez ID:
    672; 675
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer (NCT05672095)
    Phase 1/2
    City of Hope Medical Center
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/18/2025
    Primary completion :
    11/27/2026
    Completion :
    11/27/2026
    BRCA
    |
    BRCA wild-type
    |
    Zejula (niraparib)
    Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery (SALVOVAR) (NCT06476184)
    Phase 3
    ARCAGY/ GINECO GROUP
    Recruiting
    Last update posted :
    11/18/2024
    Initiation :
    08/05/2024
    Primary completion :
    06/01/2027
    Completion :
    06/01/2028
    HRD • BRCA
    |
    HRD • BRCA wild-type • BRCA mutation
    |
    carboplatin • paclitaxel
    Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (NCT04240106)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/16/2024
    Initiation :
    06/15/2020
    Primary completion :
    11/17/2022
    Completion :
    11/17/2023
    HER-2 • ER • PGR • BRCA1 • BRCA2 • HRD • BRCA • RAD51
    |
    HER-2 positive • HR positive • HER-2 negative • HRD • BRCA wild-type • HR positive + HER-2 negative
    |
    Zejula (niraparib)
    Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA) (NCT04274426)
    Phase 2
    AGO Research GmbH
    Recruiting
    Last update posted :
    01/15/2024
    Initiation :
    10/13/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2 • FOLR1 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal
    The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer (REFIRM) (NCT06086665)
    Phase N/A
    Asan Medical Center
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    12/01/2019
    Primary completion :
    10/31/2022
    Completion :
    10/31/2022
    BRCA
    |
    BRCA wild-type • BRCA mutation
    |
    Zejula (niraparib)
    First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer (NCT06063070)
    Phase 2
    Sun Yat-sen University
    Not yet recruiting
    Last update posted :
    10/02/2023
    Initiation :
    10/18/2023
    Primary completion :
    01/31/2025
    Completion :
    10/30/2027
    BRCA1 • BRCA2
    |
    BRCA wild-type
    |
    Avastin (bevacizumab) • AiRuiYi (fluzoparib)
    Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours (NCT02482311)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    07/03/2023
    Initiation :
    07/01/2015
    Primary completion :
    01/25/2018
    Completion :
    08/22/2019
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    adavosertib (AZD1775)
    A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (NCT02797977)
    Phase 1/2
    Sierra Oncology LLC - a GSK company
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    07/01/2016
    Primary completion :
    04/08/2020
    Completion :
    04/08/2020
    TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA
    |
    MSI-H/dMMR • BRCA wild-type
    |
    cisplatin • gemcitabine • SRA737
    A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA) (NCT02354586)
    Phase 2
    Tesaro, Inc.
    Completed
    Last update posted :
    09/15/2022
    Initiation :
    03/23/2015
    Primary completion :
    02/28/2018
    Completion :
    08/23/2021
    HRD • BRCA
    |
    HRD • BRCA wild-type
    |
    Zejula (niraparib)